MYC and diffuse large B-cell lymphoma: Among Myc+/Bcl-2+ patients, CXCR4 expression had an additive adverse impact in patients with GCB-DLBCL (Figures 3O-P, P= .08 for OS and P= .06 for PFS), but this impact was not statistically significant in patients with ABC-DLBCL (Supplemental Figures 1K-L).